Global Follicle Stimulating Hormone market size (most likely outcome) will be a year-over-year revenue growth rate of XX% in 2021, from US$ 1216.9 million in 2020. Over the next five years the Follicle Stimulating Hormone market will register a 2.9% CAGR in terms of revenue, the global market size will reach US$ 1364.6 million by 2027.
By 2027, the global folicle stimulating hormone market is expected to be worth USD 1364.6 million. The rising number of infertility patients seeking treatment, as well as the increasing adoption of Assisted Reproductive Technology (ART) for fertility control in countries like India, China, and Brazil, are driving the FSH market.
FSH is a glycoprotein that stimulates the follicles. It promotes spermatogenesis and the formation of follicles in the ovaries. FSH is utilised in infertile women for ovarian stimulation, puberty induction, menstrual cycle management during polycystic ovary syndrome (PCOS), spermiogenesis, and luteinization.
The report also assesses the key opportunities in the Follicle Stimulating Hormone market and outlines the factors that are and will be driving the growth of the industry. Growth of the overall global Follicle Stimulating Hormone Market has also been forecasted for the period 2022-2027, taking into consideration the previous growth patterns, the growth drivers and the current and future trends.
Top Key players in the Follicle Stimulating Hormone Market have been identified through secondary research, and their market shares have been determined through primary and secondary research. The global Follicle Stimulating Hormone Market is fragmented with a large number of small players operating worldwide. The companies referred in the market research report includes Merck Serono, MSD, IBSA, Ferring, Livzon, Techwell, GenSci, Gedeon Richter, Teva and others.
April 29, 2022
Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that the European Commission has approved KEYTRUDA, Merck’s anti-PD-1 therapy, as monotherapy for the treatment of microsatellite instability-high (MSI-H) or deficient mismatch repair (dMMR) tumors in adults with: unresectable or metastatic colorectal cancer after previous fluoropyrimidine-based combination therapy
Global Follicle Stimulating Hormone Market research provides a detailed Analytical Insights of global market size, regional and country-level scope, segmentation wise growth, global share, Competition Scenario, sales analysis, impact global market players on domestic players, value chain optimization, trade regulations, Latest developments, future opportunities, product launches, expanding marketplaces, and New technological innovations.
Follicle Stimulating Hormone Market is segmented based on the type, applications, companies and regions.
By Type, Follicle Stimulating Hormone Market has been segmented into
The end user’s industry application on Follicle Stimulating Hormone Market is,
Regional Analysis:
North America commanded a sizable market share, owing to increased awareness of infertility as a result of an unhealthy lifestyle and food. Increased patient visits to gynaecologists are expected to influence regional market growth. The region has seen a high level of adoption of FSH products, as well as the availability of appropriate infrastructure. Asia Pacific, on the other hand, is projected to acquire market traction in the near future, thanks to a huge patient pool and widespread use of FSH tests. Furthermore, prominent competitors' presence and company expansion plans are impacting regional market growth in the next years.
The report offers in-depth assessment of the growth and other aspects of the Follicle Stimulating Hormone Market in important regions, including the U.S., Canada, Germany, France, U.K., Italy, Russia, China, Japan, South Korea, Taiwan, Southeast Asia, Mexico, and Brazil, etc. Key regions covered in the report are North America, Europe, Asia-Pacific and Latin America.
Follicle Stimulating Hormone Market highlights the potential growth opportunities in upcoming years, while reviewing the market drivers, restraints, growth indicators, challenges, market dynamics, competitive landscape and other key aspects in the global market. The Global Follicle Stimulating Hormone Market report also conducted a PESTEL analysis of the industry to study the main influencing factors and entry barriers of the industry. This Research Study compares the markets of Pre COVID-19 and Post COVID-19 with the impact of COVID-19 on the regional economy.
Report Attributes
|
Report Details |
Forecast Period 2022 to 2027 CAGR |
CAGR of 2.9% during the review period (2022 to 2027). |
By Type |
|
By Application |
|
By Companies
| Merck Serono, MSD, IBSA, Ferring, Livzon, Techwell, GenSci, Gedeon Richter, Teva and others. |
Regions Covered
|
|
Countries Covered |
|
Base Year
|
2022 |
Historical Year
|
2017 to 2021 |
Forecast Year
|
2022 to 2027 |
Customization Available
|
Yes, the report can be customized as per your needs |
Key Takeaways from this Follicle Stimulating Hormone Report
All our reports are customizable to your company needs to a certain extent, we do provide 5 free consulting hours along with purchase of each report, and this will allow you to request any additional data to customize the report to your needs.
The Relay Market is studied from 2022 - 2027.
What is the growth rate of Follicle Stimulating Hormone market?
The Relay Market is growing at a CAGR of 2.9% over the next 5 years.
Who are the key players in Follicle Stimulating Hormone market?
Merck Serono, MSD, IBSA, Ferring, Livzon, Techwell, GenSci, Gedeon Richter, Teva and others.
What region does this Follicle Stimulating Hormone market report covers?
North America (the United States, Canada, and Mexico) Europe (Germany, France, UK, Russia, and Italy) Asia-Pacific (China, Japan, Korea, India, and Southeast Asia) South America (Brazil, Argentina, Colombia, etc.) The Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria, and South Africa)
What are the significant types of Follicle Stimulating Hormone market?
Infertility Treatment, Assisted Reproductive Technology
What are the major end-use applications of Follicle Stimulating Hormone market?
Recombinant FSH, Urinary FSH
SECONDARY RESEARCH
Secondary Research Information is collected from a number of publicly available as well as paid databases. Public sources involve publications by different associations and governments, annual reports and statements of companies, white papers and research publications by recognized industry experts and renowned academia etc. Paid data sources include third party authentic industry databases.
PRIMARY RESEARCH
Once data collection is done through secondary research, primary interviews are conducted with different stakeholders across the value chain like manufacturers, distributors, ingredient/input suppliers, end customers and other key opinion leaders of the industry. Primary research is used both to validate the data points obtained from secondary research and to fill in the data gaps after secondary research.
MARKET ENGINEERING
The market engineering phase involves analyzing the data collected, market breakdown and forecasting. Macroeconomic indicators and bottom-up and top-down approaches are used to arrive at a complete set of data points that give way to valuable qualitative and quantitative insights. Each data point is verified by the process of data triangulation to validate the numbers and arrive at close estimates.
EXPERT VALIDATION
The market engineered data is verified and validated by a number of experts, both in-house and external.
REPORT WRITING/ PRESENTATION
After the data is curated by the mentioned highly sophisticated process, the analysts begin to write the report. Garnering insights from data and forecasts, insights are drawn to visualize the entire ecosystem in a single report.
Reach us with your research requirements and we shall provide the optimum solution to suit your needs.
Discounts available for multiple report purchases.
